News & Events

News

View All News

English | French

January 18th, 2022

ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability

IPA Europe’s Oss laboratories make a move to new Centre of Excellence facilities in Oss, Netherlands, with progressive environmental impact measures.VICTORIA, BRITISH COLUMBIA and OSS, The Netherlands, January 17,…

January 11th, 2022

ImmunoPrecise Antibodies Announces Grant of Stock Options

VICTORIA, British Columbia – January 11, 2022 – IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that…

January 3rd, 2022

ImmunoPrecise Antibodies Announces Grant of Stock Options

VICTORIA, British Columbia – January 3, 2022–IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that its board…